TuisABUS • NASDAQ
add
Arbutus Biopharma Corp
Vorige sluiting
$2,72
Dagwisseling
$2,70 - $2,78
Jaarwisseling
$1,69 - $3,29
Markkapitalisasie
491,88 m USD
Gemiddelde volume
1,62 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
The Motley Fool
2 uur gelede
Nasdaq Bull Market: Here's the Best Investing Move You Can Make Right Now
2,03%
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Inkomste | 2,14 m | -65,65% |
Bedryfskoste | 5,10 m | 20,05% |
Netto inkomste | -19,31 m | 11,95% |
Netto winsgrens | -900,33 | -156,37% |
Wins per aandeel | -0,16 | 14,52% |
EBITDA | -20,16 m | 2,35% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 126,00 m | -14,23% |
Totale bates | 144,40 m | -26,11% |
Totale aanspreeklikheid | 38,38 m | -34,46% |
Totale ekwiteit | 106,02 m | — |
Uitstaande aandele | 179,49 m | — |
Prys om te bespreek | 4,39 | — |
Opbrengs op bates | -33,86% | — |
Opbrengs op kapitaal | -42,03% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2023info | J/J-verandering |
|---|---|---|
Netto inkomste | -19,31 m | 11,95% |
Kontant van bedrywe | -17,29 m | -1,78% |
Kontant van beleggings | 22,22 m | 75,25% |
Kontant van finansiering | 3,81 m | -65,65% |
Netto kontantverandering | 8,75 m | 29,27% |
Beskikbare kontantvloei | -9,22 m | -135,28% |
Meer oor
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia
Gestig
2007
Webwerf
Werknemers
73
